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Abstract
Vaccines were invented through the advancements of technology and medicine
to prevent premature death caused by infectious diseases. Although vaccines are a
great way to inhibit the spread of disease, their disbursement to the population is
a major component of their success. Both single and multi-dose vaccines require
diligent planning to immunize the population. Even today, outbreaks of vaccine-
preventable diseases such as pertussis and measles still occur in the United States.
The purpose of this study is to examine the dynamics of multi-dose vaccines for
diseases such as pertussis, with a particular goal of identifying circumstances when
multiple doses are necessary for disease control. One of the basic models used in
mathematical epidemiology is called the susceptible, infected, and recovered (SIR)
model. In this modeling technique, the population dynamics are studied by dividing
the population into susceptible, infected, and recovered individuals. In this project
we plan to analyze the dynamics of a two-dose vaccination program by introducing
a new class of vaccinated individuals to the basic SIR model. We explore if it is
possible to have a single dose vaccine for an infectious disease such as pertussis.
Further, the disease free equilibrium and its global stability are studied as is the
endemic equilibrium and its local stability. We also calculate the critical vaccination
rate. This is the minimum vaccination rate needed to eliminate disease from the
population. Furthermore, this study looks into the number of secondary infections
caused by an infected individual. This is called the basic reproduction number and
it is specific to each type of model. These results characterize the epidemiological
model. In conclusion, we find that a single dose vaccine for pertussis is only effective
if there is a very low waning immunity from the first dose of vaccine. In any other
instance, there must be a two-dose vaccination for the disease. The model can be
further expanded to multiple doses, depending on the type of disease.
1 Introduction
The average lifespan of individuals born in 1900 was less than 55 years. Today it has
increased, and the average lifespan now is greater than 75 years [15]. A significant
reason for this has been the great number of advancements in medicine and tech-
nology, particularly with the introduction of vaccination. In 1796, Edward Jenner
created the first vaccine for smallpox from a live cowpox virus. Many scientists and
doctors followed his path and were able to create more vaccines to other diseases.
Likewise, Louis Pasteur developed a vaccine for rabies in 1880s. In the 1940s, a
vaccine for polio was created by Dr. Jonas Salk. In the 1930s, Dr. Leila Denmark
discovered a vaccine for pertussis. Vaccination has had a major effect in disease
control both in the developed and developing nations. Several prominent diseases
such as measles, mumps, rubella, hepatitis B, and pertussis are now preventable
with the use of such vaccines. For vaccines to be effective, they must be disbursed
to the population in a timely manner. Many of the vaccines require more than one
dose over a lifetime, and the planning involved in its disbursement is crucial to its
success. Let us now discuss some common vaccine preventable diseases.
One of the vaccine-preventable diseases is Hepatitis-B. One in twenty people
in the United States show some sign of being affected by the Hepatitis-B Virus
(HBV). HBV is a significant health concern not only in the United States, but also
worldwide. In the United States an estimated 4000 to 6000 new infections occur
each year in adolescents and children [1]. Some patients become chronically infected,
which in turn serves as a reservoir for the future spread of HBV. Immunization of all
newborn children is a strong step towards eradicating HBV. There are three common
forms of the HBV vaccine: Recombivax HB, Engerix-B, and Comvax. Recombivax
HB and Engerix-B share a similar time line in their disbursement. For the most part
both of these vaccines are administered in three doses. They are given at 0 months,
1 month, and 6 months. Comvax has a different schedule, but also is given in three
doses. Comvax is given at 2 months, 4 months, and once in 12 − 15 months [1].
HBV is unfortunately still one of the most prevalent blood-borne diseases, however
it can be eradicated by the proper use of vaccines towards newborns and children.
Measles, Mumps and Rubella are three diseases that are also preventable by
using the MMR vaccine. However, there still have been a few outbreaks in the
United States. In fact, there was a mumps outbreak recently at The Ohio State
University in 2014. From 2000− 2012 there have been 1, 135 reported mumps cases
in the United States [3]. Measles is another serious illness. In many occurrences
it has lead to severe complications as well as death. The frequently recommended
vaccine strategy is a two-dose regimen. The first dose is given to infants at the
age of 12 − 15 months and the second dose is administered at 4 − 6 years of age.
The second dose is not considered to be a booster vaccine. Instead, the purpose
of this dose is to provide immunity to those who do not respond to the first dose.
Approximately 2 − 5% of people do not develop immunity after the first dose of
the MMR vaccine [3]. The most significant measles outbreak occurred in Ohio’s
Amish communities. A group of unvaccinated Amish missionaries had just returned
from the Philippines and brought the disease with them and it spread quickly here
at home [17]. Since there is little to no vaccination in these communities, measles
posed to be a significant health risk for the Amish population. Interventions by the
Ohio Department of Health was able to minimize these effects.
Similarly, pertussis is another example of a vaccine preventable disease. Since
the 1990s there has been an increase in the number of reported pertussis cases in
the United States. This has been noticed specifically among children upto the age
of 19 [7]. There are many possible reasons as to why the spread of pertussis has
increased, including a waning immunity in the acellular vaccine (DTaP) or possibly
increased recognition of pertussis [4]. DTaP is a vaccine given to infants at birth.
This protects children from pertussis, tetanus, and diphtheria. Since 2013, Tdap
(the second booster shot) is usually administered in the 7th grade [5, 12]. Some
feel that it is important to reinforce the current vaccination program and add to it
another booster program for the most affected age groups [6]. Not all countries are
capable of sustaining a two-dose program for pertussis, and certainly would not be
able to fund a multi-dose pertussis model [16]. So the following question arises: is
it possible to create a single dose pertussis vaccination program that could replace
a two-dose pertussis vaccination strategy? We find, if ω is small enough then it is
possible to implement an effective single dose vaccine strategy. In this undergraduate
thesis, this question will be investigated by developing and analyzing a multi-dose
vaccine model, more specifically the susceptible, infected, vaccinated and recovered
(SIVR) model.
2 The Model
The SIVR model used here comes from the original susceptible, infected, and re-
moved (SIR) epidemiological model developed by Kermack and McKendrick [20].
Kermack and McKendrick’s SIR model was revolutionary for its time. Today the
SIR model is one of the cornerstones of Mathematical Epidemiology. While assum-
ing constant birth and death, this model divided the population into three different
classes, susceptible (S), infected (I), and removed (R). The Susceptible portion of
the population were those who have not acquired the disease, Infected are the por-
tion of the population that are infected from the disease, and Removed are those
who have either recovered from the disease or have died from it. The SIR model
was first used to explain great epidemiologic events such as the London Cholera
Epidemic of 1865 [18]. This figure shows a flow diagram of the SIR model:
 
Figure 1: SIR Flow Diagram
The following differential equations characterize the basic SIR model:
S˙ = µN − βSI − µS
I˙ = βSI − γI − µI
R˙ = γI − µR.
(1)
.
The aim of this thesis is to study the dynamics of an SIR model with an addi-
tional vaccinated class. The vaccinated class contains those individuals who have
gained partial or temporary immunity by receiving the first dose. The basic SIR
model was modified to accommodate for a vaccinated class resulting in the SIVR
model. The SIVR model problem is derived from work done on Optimal Vaccination
Strategy for a two-Dose Vaccination Model by Kelly, Lenhart, Tien, and Eisenberg
(personal communication, Tien). The basic framework for this model stems from
Kermack and McKendrick’s original SIR model [20]. In comparison to the SIR
model a new “V ” class of vaccinated individuals is added to the basic SIR model.
This enables us to be able to study the dynamics of vaccinating a population. Like
in many SIR models, this SIVR model will be treated as a compartmental ordinary
differential equations (ODE) model. The model is assumed to have the same condi-
tions of constant population size. Susceptible individuals can either be infected or
vaccinated. Those who become infected later move on to the removed class. Those
individuals who do get the first dose of the vaccine move to the vaccinated class at
the rate of ψ. Further, if this population receives the second dose then it moves to
the removed class at the rate of p. Additionally, if this population does not receive
the second dose of the vaccine, then it moves back to the susceptible population at
the rate of ω. The following figure is a flow diagram of the SIVR model that is the
center of this thesis:
 
Figure 2: SIVR Flow Diagram
These are the differential equations that characterize the SIVR model:
S˙ =
dS
dt
= −µS + µN − ψS + ωV − bIIS
I˙ =
dI
dt
= −µI + bIIS − νI
V˙ =
dV
dt
= −µV + ψS − ωV − pV
R˙ =
dR
dt
= −µR+ νI + pV.
(2)
.
Table 1: Variables for the SIVR model
S susceptible individual density individuals km−2
I infected individual density individuals km−2
V vaccinated individual density individuals km−2
R recovered/removed individual density individuals km−2
N total population density individuals km−2
Since we have assumed a constant population size it can be noticed that N =
S + I + V +R.
Table 2: Parameters for the SIVR model
Parameters Interpretation Values/Units Source
µ birth and death rate 0.0035342 births and deaths/day [10]
ψ rate of first dose of vaccine 0.00020185263/day [11]
1
ω
time first dose wanes in immunity 10 years approximated
bIN = β person-person contact rate varies/day fitting model
ν recovery rate 0.0476/day [10, 9]
1
p
time between first and second dose 13 years [12]
3 Analysis of the Model
In this section we will analyze the dynamics of the SIVR model.
3.1 Disease Free Equilibrium
Finding the steady states is one of the first steps in analyzing any dynamical sys-
tem. The two important states of this system of equations are the Disease Free
Equilibrium (DFE) and Endemic Equilibrium (EE). The disease free equilibrium is
where there is no disease in the system. The endemic equilibrium is a state where
the disease always remains present without any re-introduction of the disease. In
this section we find the DFE. To do so we must set I˙ = 0 and solve. It can be seen
that S∗ =
ν + µ
bI
or I = 0. Since we are solving for the DFE here, we use I = 0.
Later on the EE will be calculated, then S∗ =
ν + µ
bI
is used to find all the steady
states. Implementing I = 0 into our system, the equations change to:
(i) S˙ = −µS + µN − ψS + ωV,
(ii) R˙ = −µR+ pV,
(iii) V˙ = −µV + ψS − ωV − pV.
(3)
To solve for the DFE, we set the new S˙, R˙, and V˙ = 0 and find the DFE. Since
we have three unknowns and three equations, we use multiple substitutions to solve.
Using (ii), we have that R =
pV
µ
.
Using (i), we have that S =
µN + ωV
µ+ ψ
.
Using (iii), we have that V =
ψS
(µ+ ω + p)
.
Using S that we have found above, we substitute this in and simplify the expres-
sion to get
V =
ψ
µ+ ω + p
µN(µ+ ψ)(µ+ ω + p)
(µ+ ψ)[(µ+ ψ)(µ+ ω + p)− ωψ] ,
S =
µN(µ+ ψ)(µ+ ω + p)
(µ+ ψ)[(µ+ ψ)(µ+ ω + p)− ωψ] .
3.2 Basic Reproduction Number
R0 is the basic reproduction number of a disease and is a critical component of
any epidemiological model. This is also characterized as the number of secondary
infections created from a single infection. By analyzing the value of R0 we can make
a claim if the disease will spread within a population or if it will go to extinction.
If R0 > 1 we find the DFE is unstable and the disease persists, and if R0 ≤ 1 then
the DFE is stable and it dies out (Theorem 2 in [8]). To gain more insight, R0 is
calculated for the SIVR model in this project. The calculation is completed using
the next generation matrix method found in [8]. To implement this method, we
take that I˙ as the only equation carrying infected individuals and the “V ” class
does not contribute any infections. We will will notice that this closely resembles
the SIR model. Under these conditions, we formulate F , the rate of appearance of
new infections in compartment, and V , the rate of transfer of infected individuals
in and out of compartment.
For the SIVR model we have that F = bIIS and V = I(µ+ ν).
Then, by taking the derivative with respect to I, we have that
F = bIS and V = µ+ ν. Further, we find that V
−1 =
1
µ+ ν
.
From [8] we know that R0 is calculated finding the spectral radius of (FV
−1),
also written as R0 = ρ(FV
−1). This is done by finding the eigenvalue of FV −1 [8].
Applying this to the model in this project, it is found that:
ρ(FV −1) = ρ(
bIS
µ+ ν
).
As we assume that there is no vaccination, then it is the case that S = N at
the DFE. So, we find that R0 =
bIN
µ+ ν
. Interestingly, we see that this is exactly the
same as the R0 of an SIR model due to the fact that there is no vaccination.
3.3 Endemic Equilibrium
As mentioned previously, there are two steady states, the DFE and EE. In this
section, the EE is solved for.
By setting I˙ = 0 it can be seen that S∗ =
ν + µ
bI
or I = 0. To solve for the EE,
we use S∗. Before we do so, we can take a moment to realize that
S∗
N
=
1
R0
. We
will discuss this later on. Let us continue to calculate the EE.
Knowing S∗ =
ν + µ
bI
, we set V˙ = 0 and solve for V ∗:
V ∗ = ψ

(ν + µ)
bI
(µ+ ω + p)

Likewise, we set R˙ = 0 and solve for I∗ and R∗, giving
I∗ = − µ
bI
+
µN
(ν + µ)
− ψ
bI
+
ωψ
bI(µ+ ω + p)
,
R∗ =
ν
µ
[
− µ
bI
+
µN
(ν + µ)
− ψ
bI
+
ωψ
bI(µ+ ω + p)
]
+
p
µ
ψ
(ν + µ)
bI
(µ+ ω + p)
.
We can parametrize these steady states I∗, V ∗, and R∗ in terms of R0. This is
accomplished in a later section. Once we have completed solving for the steady states
we arrive at the endemic equilibrium for the SIVR model, written as (S∗, I∗, R∗, V ∗).
If we compare these steady states with those of the SIR model, we observe that S∗
is very similar. Likewise, we see a resemblance in the other steady states as well.
This is logical, as the SIVR model is quite similar to the SIR model.
3.4 Local Stability of Endemic Equilibrium
To further the analysis of the dynamical system we analyze the stability of the
endemic equilibrium. To do so, the system of equations is linearized and evaluated
at the fixed point (where S˙ = I˙ = V˙ = R˙ = 0). In a one dimensional system, we
evaluate the derivative of the function at the fixed point. The resulting slope is either
positive or negative. If it is positive then this shows that a small perturbation will
grow exponentially and if it is negative then the perturbation decays. This studies
the local stability of the fixed point ([13], pages 24-25). In the SIVR model we have
a three dimensional system (since R is decoupled from S, I, and V ). The three
dimensional linearization analog is attained through the Jacobian. As a result, we
have a 3 x 3 Jacobian matrix. If the real parts of the eigenvalues are found to be
less than zero, then this shows that the point is locally stable ([14], pages 233-235).
The Jacobian of the SIVR model is computed below:
J =
∣∣∣∣∣∣∣∣
−µ− ψ − bII −bIS 0 ω
bII −µ+ bIS − ν 0 0
0 ν −µ p
ψ 0 0 −µ− ω − p
∣∣∣∣∣∣∣∣
The next step is to evaluate the Jacobian at the endemic equilibrium (S∗, I∗, R∗, V ∗)
found in the preceding section and find the eigenvalues of J by solving det(J − λ ∗
Id) = 0 for λ.
After the completing the calculation we simplify the characteristic equation as
such:
λ3 + λ2α1 + λα2 + α3 = 0,
where
α1 = 2µ+ ω + p+ bII + ψ
α2 = µ
2 + ωµ+ pµ+ µψ + pψ + bIµI + bIνI + µbII + ωbII + pbII
α3 = µ
2bII + µbIνI + ωbIµI + ωbIνI + pbIµI + pbIνI.
To guarantee the real parts of the eigenvalues are less than zero for a 3 x 3
system, the following criteria must be met: α1 > 0, α3 > 0, and α1α2 > α3 ([14],
pages 233-235). It can be noticed that α1 consists of five non-negative terms, α2
consists of ten non-negative terms, and α3 consists of eight non-negative terms. As
we multiply α1 by α2 we find that it is equal to α3 + Λ, where Λ is the remaining
positive terms. Then, we see that α1α2 - α3 = Λ > 0. So, α1α2 > α3. Since
the criteria for the Routh-Hurwitz Stability criterion are met and the real parts of
the eigenvalues are less than zero, this is stable in a local environment around the
endemic equilibrium. This implies that if there is a small perturbation away from
this point, then the system will move back to the endemic equilibrium. This criteria
does not make an assertion on its Global Dynamics.
3.5 Critical Vaccination Rate
Vaccinating an entire population for a specific disease is not always possible and
is financially difficult to do. We find that it is possible to vaccinate less than the
entire population and still drive the disease to extinction. The critical vaccination
rate is the smallest rate of people that must be vaccinated to accomplish this goal.
If ψ < ψcrit, then the disease converges to the EE.
To find the critical vaccination rate we solve for ψ from the Endemic Equilibrium
for I = 0.We find that
ψcrit = µ
µ+ ω + p
µ+ p
(R0 − 1).
If R0 < 1 then there is no need to vaccinate anyone. This makes sense, because
if R0 < 1 then the disease will never spread. So, there is a need to vaccinate the
population if R0 > 1, because then the disease will spread. The critical vaccination
rate for an SIR model is: ψcrit = µ(R0− 1). Both critical vaccination rates are very
similar, the difference lies in the factor of
µ+ ω + p
µ+ p
. This is fraction is greater than
one. However, if ω is very small then,
µ+ ω + p
µ+ p
≈= µ+ p
µ+ p
= 1.
Then the critical vaccination rate of the SIVR model is approximately the same
as that of the SIR model if the waning immunity of the vaccine is small. Further
analysis of this case is conducted in the conclusion of this thesis.
3.6 Re-Parametrize the Equations
To further our understanding of this dynamical system we non-dimensionalize the
differential equations. By doing this we are able to see important groupings of
parameters such as R0.
Let W =
S
N
, X =
I
N
, Y =
R
N
, Z =
V
N
, and l = bIN . Then the corresponding
differential equations are
dW
dt
=
1
N
∗ dS
dt
= −µW + µ− ψW + ωZ − lXW
dX
dt
=
1
N
∗ dI
dt
= −µX + lXW − νX
dZ
dt
=
1
N
∗ dV
dt
= −µZ + ψW − ωZ − pZ.
dY
dt
=
1
N
∗ dR
dt
= −µY + νX + pZ
(4)
Now we re-scale the parameters to R0 =
bIN
µ+ ν
=
l
µ+ ν
. In this process we
introduce new parameters:
a =
ψ
µ+ ν
, b =
µ
µ+ ν
, c =
ω
µ+ ν
, d =
ν
µ+ ν
, f =
p
µ+ ν
.
Here we are scaling time with respect to the infectious period (µ + ν), where
τ = (µ+ ν)t. Now we have:
W˙ =
dW
dτ
= −W (a+ b) + b+ cZ −R0XW
X˙ =
dX
dτ
= −X +R0XW
Z˙ =
dZ
dτ
= −bZ + aW − cZ − fZ
Y˙ =
dY
dτ
= −bY + dX + fZ
Then we calculate the equilibrium points again, by the same technique as earlier.
We find that:
W ∗ =
1
R0
X∗ = b+
ca
R0(b+ c+ f)
− b
R0
− a
R0
Z∗ =
a
R0(b+ c+ f)
Y ∗ =
d
b
(
b+
ca
R0(b+ c+ f)
− b
R0
− a
R0
)
+
a
R0(b+ c+ f)
(
f
b
)
Similarly we compute the critical vaccination rate in terms of the new variables.
From X∗ we solve for a, then:
acrit = a = b
b+ c+ f
b+ f
(R0 − 1).
The DFE is also calculated for this reparameterized version of the model:
W ∗ =
b
(a+ b)− ca
b+ c+ f
and
Z∗ =
a
b+ c+ f
 b
(a+ b)− ca
b+ c+ f
.
3.7 Global Stability at the DFE for R0 ≤ 1
Earlier we calculated the EE and made an assertion about its local stability. Here
we are trying to explore the global stability of the DFE. Global stability is a much
stronger condition than local stability. It says that it the system converges to a
specific point regardless of the initial condition, whereas local stability can only
comment about the local environment of a steady state.
Let s =
S
N
, i =
I
N
, v =
V
N
, and bIN = β. Then
s˙ = −µs+ µ− ψs+ ωv − βis,
i = −µi+ βis− νi,
v˙ = −µv + ψs− ωv − pv
(5)
We only look at s˙, i, and v˙ since r˙ is decoupled from the other equations. By
making this parametrization, we also know that s, i, and v are ≤ 1. To analyze the
global stability of this dynamical system let us first look at the these parametrized
equations in the s and v plane. For R0 ≤ 1 our inclination is that the i equation
will go to the set i = 0. To show this, we must rule out any periodic solutions. This
can be achieved by using a Liapunov function or Dulac’s Criterion among other
techniques. To show that the set will converge to i = 0, we consider a Liapunov
function. A Liapunov function is a continuously differentiable, real valued function
F (x) where F (x) > 0 for all x 6= x∗ and F (x∗) = 0. Furthermore, F˙ < 0 for all
x 6= x∗. If these conditions are satisfied, then we can say that x∗ is globally stable for
all initial conditions ([13], pages 151-152). For this model we consider a Liapunov
function whose form comes from Theorem 5.1 in [2].
Let
F =
1
µ+ ν
i. (6)
Then,
F˙ = − µ
µ+ ν
i+
β
µ+ ν
is− ν
µ+ ν
i. (7)
By further simplifying this, we get
F˙ = i(R0s− 1). (8)
It can be easily seen that F = 0 at s∗ and i∗ and F > 0 for all other values
of s and i. Furthermore, we see that F˙ ≤ 0 , R0 ≤ 1, and s˙ ≤ 1. Since this is a
Liapunov function and since this is a decreasing and bounded function we can say
that this will converge to the set where i = 0. Knowing that i = 0, the equations at
the beginning of this section are re-evaluated. Then we achieve the following set of
equations
s˙ = −µs+ µ− ψs+ ωv
v˙ = −µv + ψs− ωv − pv. (9)
Further exploration of the global stability of this system is completed using
Dulac’s Criterion. For a planar vector field, Dulac’s Criterion says that let x˙ = f(x)
be continuously differentiable. If there exists a continuously differentiable, real-
valued function g(x) such that ∇(gx˙) maintains only one sign on a simply connected
set, then there are no periodic orbits in this set ([13], pages 203-204). Let us consider
∇(gx˙) = ∂
∂s
(gs˙) +
∂
∂v
(gv˙) (10)
where we take g = 1.
Then we have,
∇(gx˙) = ∂
∂s
(s˙) +
∂
∂v
(v˙)
= −µ− ψ − µ− ω − p < 0.
Thus, the SIVR model is globally stable by Dulac’s Criterion for R0 ≤ 1. This
should then converge to the equilibrium regardless of any initial condition given
that R0 ≤ 1. In this thesis we use Matlab to create simulations to better study
the SIVR model. We use the initial conditions where the initial population of the
S class is 0.9999, I class is 0.0001, and V class is 0 (also x-axis t represents time
in days). In figure 3 we can see that the Matlab simulation reflects the theoretical
results presented in this section.
Figure 3: β = 0.03, ψ = 0.00020185, µ = 0.000035342, ν = 0.0476, p = (1/4380), ω =
(1/3650) For R0 < 1 the SIVR model converges to the DFE as suggested by the
theoretical results
The presence of a vaccinated class in the SIVR model poses a difficulty in proving
global stability of the endemic equilibrium for R0 > 1. This question may be of
interest to look into in the future. It is attempted to make an observation on this
matter by observing the Matlab simulation for R0 > 1, specifically R0 = 5.5 [19].
In figure 4, we compute the simulation with R0 > 1 and ψ > ψcrit. This does not
converge to the EE, but to the DFE. This makes sense. If we are vaccinating at a
rate higher than the critical vaccination rate, then it should converge to the DFE.
Figure 4: β = 0.261994381, ψ = 0.000471498, µ = 0.000035342, ν = 0.0476, p =
(1/4380), ω = (1/3650) For ψ > ψcrit the simulation suggests that the SIVR model
converges to the DFE
In figure 5, the simulation is run again, but this time R0 > 1 and ψ < ψcrit.
Figure 5: β = 0.261994381, ψ = 0.00020185, µ = 0.000035342, ν = 0.0476, p =
(1/4380), ω = (1/3650)For ψ < ψcrit the simulation suggests that the SIVR model
converges to the EE
Looking at this case, it can be said that this converges to the endemic equilib-
rium. However, we can not say this for all cases R0 > 1. This makes sense as we are
vaccinating at rate less than the critical vaccination rate. However, we do not have
any theoretical results to affirm these claims. A Liapunov function may be created
to show this, however we did not pursue this in this thesis.
4 Conclusion and Summary
Here our aim is to complete the analysis of the model and attempt to answer the
question centered around this project. Is it better to have a two-dose pertussis
vaccination program? Is there any way to create a single dose schedule for pertussis
to reduce the financial burden in sustaining a booster program? We use matlab to
better answer these questions. Using data from [9], [10], and [11] we are able to run
simulations that give us a better insight. This first graphic shows use of a two-dose
vaccination program.
Figure 6: β = 0.261994381, ψ = 0.00020185, µ = 0.000035342, ν = 0.0476, p =
1
4380
, ω =
1
3650
We modify our SIVR model and let the parameter p (the second dose of the
vaccine) equal to 0. This creates a single dose vaccine. We again run the matlab
simulation and compare it with the previous simulation.
Figure 7: β = 0.261994381, ψ = 0.00020185, µ = 0.000035342, ν = 0.0476, p =
0, ω =
1
3650
It can be noticed that a two-dose pertussis schedule produces less infected in-
dividuals than the single dose pertussis schedule. Given the data that was used
it easy to say that it is a better idea to implement a two-dose pertussis program.
The question still persists, when will it be possible to have a single dose pertussis
program. As we look back at the V˙ equation we see that ψ, ω, and p all influence
the population of the V-class, where ω is the waning immunity. Let us consider a
situation where we have p = 0 and a small enough ω.
Figure 8: β = 0.261994381, ψ = 0.00020185, µ = 0.000035342, ν = 0.0476, p =
0, ω = (1/10950)
It can be noticed that it may be possible to create a single dose vaccine for
pertussis and still drive the disease to extinction. Let us take a look at the critical
vaccination rate under these conditions. This is the critical vaccination rate where
p = 0.
ψcrit = (µ+ ω) (R0 − 1)
Further if ω is negligibly small, then we have
ψcrit ≈ (µ) (R0 − 1)
Here we are able to recover the original critical vaccination rate of an SIR model.
Our model begins to look like the original SIR model which we know is globally
stable. This suggests that it may be possible to implement a one dose vaccine for
pertussis if ω is small enough. Literature [6] suggests that the first dose is waning
in immunity. So if a strong first vaccine is created whose immunity does not wane
(has a very small ω value), then it is possible to implement a one-dose vaccine for
pertussis. A natural question arises. What can be done to reduce ω ? There may
be many possible answers that may accomplish this goal. I think the development
of a stronger vaccine is one way to reduce the value of ω.
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